A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML).
暂无分享,去创建一个
R. Greil | M. Fiegl | H. Hausmaninger | M. Fridrik | D. Geissler | G. Gastl | W. Hilbe | W. Eisterer | H Hausmaninger | T Kühr | S Burgstaller | U Apfelbeck | W Linkesch | H Seewann | M Fridrik | G Michlmayr | O Krieger | D Lutz | W Lin | J Pont | L Köck | K Abbrederis | C Baldinger | R Buder | D Geissler | A Lang | A Zabernigg | C Duba | W Hilbe | W Eisterer | M Fiegl | R Greil | G Gastl | J Thaler | G. Gastl | O. Krieger | D. Lutz | J. Thaler | W. Linkesch | A. Zabernigg | J. Pont | G. Michlmayr | R. Buder | C. Duba | S. Burgstaller | A. Lang | T. Kühr | K. Abbrederis | C. Baldinger | G. Michlmayr | J. Pont | H. Seewann | U. Apfelbeck | L. Köck | K. Abbrederis | W. Lin | T. Kühr
[1] G. Utermann,et al. Hypermetaphase and interphase fluorescence in situ hybridisation for monitoring of remission status in Philadelphia chromosome positive chronic myeloid leukaemia. , 2000, International journal of oncology.
[2] R Ohno,et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. , 1995, Blood.
[3] Z. Aziz,et al. A Prospective Randomized Study of Alpha-2b Interferon plus Hydroxyurea or Cytarabine for Patients with Early Chronic Phase Chronic Myelogenous Leukemia: The International Oncology Study Group CML1 Study , 2000, Leukemia & lymphoma.
[4] Lindauer,et al. Efficacy and toxicity of IFN‐α2b combined with cytarabine in chronic myelogenous leukaemia , 1999 .
[5] H. Heimpel,et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. , 1994, Blood.
[6] D. Ma,et al. Combined interferon alfa-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia. , 1993, Acta haematologica.
[7] W. Hilbe,et al. Comparative analysis of two consecutive phase II studies with IFN-alpha and IFN-alpha + ara-C in untreated chronic-phase CML patients. Austrian CML Study Group. , 1996, Bone marrow transplantation.
[8] S. Richards,et al. UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response , 1995, The Lancet.
[9] R. Kurzrock,et al. Therapy of chronic myelogenous leukemia with interferon. , 1989, Cancer investigation.
[10] M. Andreeff,et al. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] H. Kantarjian,et al. Prolonged Survival in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon- Therapy , 1995, Annals of Internal Medicine.
[12] S. Woolf,et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. , 1999, Blood.